Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2005 ... (Hep C Treatment)

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2005 ...
PR Newswire (press release), NY - Feb 23, 2006... ANA975 designed to evaluate the safety and tolerability of ANA975 and the viral load reduction achieved in patients with chronic hepatitis C over 28 days. ...

MIGENIX Reports Third Quarter Fiscal Year 2006 Results
MSN Money - Mar 8, 2006... development programs, with two phase II clinical outcomes expected this year in our MX-3253 program for the treatment of chronic hepatitis C virus infections ...

Toll-like receptor therapies compete to reduce side effects
Nature.com (subscription), UK - Mar 6, 2006... CSO, claims that ANA975, the company's TLR7 agonist, recently tested in a 28-day clinical trial involving patients with chronic hepatitis C, could produce ...

Nature Reviews Drug Discovery Writes On AVI BioPharma's NEUGENE ...
Trading Markets, CA - Mar 7, 2006... AVI is currently enrolling patients with chronic hepatitis C infection in a Phase I/II clinical trial in the US The company has also reported early success in ...

Human Genome Sciences up on drug outlook
BusinessWeek - Mar 1, 2006... on Wednesday after the company presented at an investor conference and provided an "upbeat" outlook for Albuferon, a possible treatment for chronic hepatitis C ...